- Market Growth Factors & Global Market Size.
- Leading Players & Top Segments.
- Geographic Overview.
Market growth influenced due to following factors-
- Opposition to animal testing.
- Technological advancements.
- Increasing R&D expenditure to detect toxicity at an early stage during drug development.
Global market size-
According to the new market research report In Vitro Toxicity Testing Market is expected to reach $14.9 billion by 2025, at a CAGR of 10.3%.
The prominent players in the in vitro toxicity testing market include Thermo Fisher Scientific Inc. (US), Covance (US), Bio-Rad Laboratories, Inc. (US), GE Healthcare (US), Eurofins Scientific SE (Luxembourg), Merck KGaA (Germany), Charles River Laboratories International, Inc. (US), Catalent, Inc. (US), Cyprotex (UK), SGS S.A. (Switzerland), QIAGEN N.V. (Germany), Promega Corporation (US), Gentronix Limited (UK), BioIVT (US), and MB Research Laboratories (US).
Top Market Segments-
Based on the technologies used in the in vitro toxicology testing, the cell culture technologies segment is expected to account for the largest share of the in vitro toxicology testing market
By product and service, the consumables segment is expected to account for the largest share of the in vitro toxicity testing market
For Details, Download PDF Brochure Here
Geographic Overview -
The APAC in vitro toxicology testing market is projected to register the highest growth during the forecast period. Factors such as emergence of CROs for outsourcing toxicology-related research projects, opposition to animal testing resulting in the use of alternate methods, increasing pharmaceutical drug pipeline, and growing consumer awareness of product safety are some of the key factors driving the growth of the market in the APAC.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.